Novo/Catalent: Buyer Negotiating Contract Extensions with Complaining Drugmakers

Published on Dec 03, 2024

Novo Holdings is negotiating contract extensions with drugmakers complaining to antitrust enforcers about its proposed $16.5 billion acquisition of pharmaceutical contract manufacturer Catalent (CTLT), sources familiar with the matter said.

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2024 The Capitol Forum. All Rights Reserved.